×
About 930 results

ALLMedicine™ Intestinal Perforation Center

Research & Reviews  337 results

Small Intestinal Perforation Secondary to Necrotizing Enteritis-An Under-Recognized Com...
https://doi.org/10.1177/00031348211054521
The American Surgeon; Huerta CT, Ribieras AJ et. al.

Jan 14th, 2022 - Small bowel perforation is an uncommon but severe event in the natural history of Crohn's disease with fewer than 100 cases reported. We review Crohn's disease cases with necrotizing enteritis and share a case of a 26-year-old female who presented...

Probiotics Supplementation and Intestinal Microbiome in Neonates With Gastrointestinal Surgery
https://clinicaltrials.gov/ct2/show/NCT03266315

Jan 11th, 2022 - Research Objectives/Question: The main objective of this study is to determine the impact of probiotics administration on the intestinal microbiome in neonates undergoing gastrointestinal surgery. Primary question: Diversity and abundance of stool...

Posterior Reversible Encephalopathy Syndrome in the Setting of Asparaginase-associated ...
https://doi.org/10.1097/MPH.0000000000002367
Journal of Pediatric Hematology/oncology; Scheuermann A, Harker-Murray P et. al.

Dec 31st, 2021 - Asparaginase, a critical component of current pediatric acute leukemia treatment protocols, is associated with a number of serious side effects, one of which is pancreatitis. Pancreatitis can result in significant morbidity and mortality from necr...

Surge of Typhoid Intestinal Perforations as Possible Result of COVID-19-Associated Dela...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632171
Emerging Infectious Diseases; Jeon HJ, Marks F et. al.

Nov 23rd, 2021 - During the coronavirus disease pandemic, we observed a 6.4-fold increase in typhoid intestinal perforation incidence in Antananarivo, Madagascar. Thirteen perforations occurred within 6 months (February 2020-July 2020), compared with 13 perforatio...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  13 results

Probiotics Supplementation and Intestinal Microbiome in Neonates With Gastrointestinal Surgery
https://clinicaltrials.gov/ct2/show/NCT03266315

Jan 11th, 2022 - Research Objectives/Question: The main objective of this study is to determine the impact of probiotics administration on the intestinal microbiome in neonates undergoing gastrointestinal surgery. Primary question: Diversity and abundance of stool...

Pathophysiology of Perioperative Fluid Management in Emergency Laparotomy
https://clinicaltrials.gov/ct2/show/NCT03997721

May 4th, 2021 - In critically ill patients and patients undergoing major surgery, the combination of internal fluid shifts and fluid retention resulting in extravascular fluid accumulation and postoperative organ dysfunctions, complicates perioperative fluid mana...

Is TIme From adMission to surgEry an Independent Prognostic Factor for Survival of Patients With Gastro-intestinal Perforation Associated With Septic Shock: (TIME) An Italian Intersocietary Retrosp...
https://clinicaltrials.gov/ct2/show/NCT04811755

Mar 23rd, 2021 - This is an Italian National multicenter study composed by a retrospective phase of data collection from patients of past ten years and a perspective one of next two years. INCLUSION AND EXCLUSION CRITERIA We include in our analysis all patients wi...

Intraductal Transanastomotic Stent in Duct-to-duct Biliary Reconstruction in Liver Transplantation
https://clinicaltrials.gov/ct2/show/NCT04804215

Mar 18th, 2021 - Aim of study Primary end-point To compare and evaluate the incidence of biliary tract complications within 6 months after surgery according to the presence or absence of an intrabiliary stent during biliary reconstruction in liver transplantation....

The Effect of Individualized Intervention on the Quality of Bowel Preparation
https://clinicaltrials.gov/ct2/show/NCT04446195

Jul 7th, 2020 - Colorectal cancer (CRC) is a malignant tumor originates from colorectal mucosa epithelium. It is one of the most common malignant tumors in the world. Incidence rate of lung cancer is second only to lung cancer and breast cancer worldwide. In rece...

see more →

News  19 results

Lenvatinib Plus Pembrolizumab May Increase OS Rates in Advanced Colorectal Cancer
https://www.onclive.com/view/lenvatinib-plus-pembrolizumab-may-increase-overall-survival-rates-in-advanced-colorectal-cancer

Jun 18th, 2021 - The combination of lenvatinib (Lenvima) plus pembrolizumab (Keytruda) was associated with clinical activity in patients with previously treated advanced colorectal cancer, according to findings from the LEAP-005 study presented at the virtual 2021...

Prolonged Treatment With Bevacizumab Does Not Yield Further Survival Benefit in Ovarian Cancer
https://www.onclive.com/view/prolonged-treatment-with-bevacizumab-does-not-yield-further-survival-benefit-in-ovarian-cancer

Jun 7th, 2021 - Although prolonged treatment with bevacizumab (Avastin) for up to 30 months is feasible with consistent safety data for patients with primary epithelial ovarian, fallopian tube, or peritoneal cancer, the regimen did not improve survival over the s...

Loncastuximab Tesirine Showcases Substantial Antitumor Activity in Heavily Pretreated Relapsed/Refractory DLBCL
https://www.onclive.com/view/loncastuximab-tesirine-showcases-substantial-antitumor-activity-in-heavily-pretreated-relapsed-refractory-dlbcl

May 18th, 2021 - Loncastuximab tesirine-lypl (Zynlonta) has demonstrated significant antitumor activity with durable responses and an acceptable toxicity profile, when used as a monotherapy in heavily pretreated patients with relapsed or refractory diffuse large B...

Olaparib Maintains Acceptable Safety Profile in Platinum-Sensitive, Relapsed Ovarian Cancer
https://www.onclive.com/view/olaparib-maintains-acceptable-safety-profile-in-platinum-sensitive-relapsed-ovarian-cancer

Mar 22nd, 2021 - Olaparib (Lynparza), when used in patients with platinum-sensitive relapsed ovarian cancer who had a known BRCA mutation and homologous recombination deficiency (HRD) status, demonstrated adverse effects (AEs) that proved to be consistent with the...

Ramucirumab/Nivolumab Combo Shows Potential in Advanced Gastric Cancer
https://www.onclive.com/view/ramucirumabnivolumab-combo-shows-potential-in-advanced-gastric-cancer

Dec 20th, 2020 - The combination of nivolumab (Opdivo) and ramucirumab (Cyramza) has activity in patients with previously treated advanced gastric adenocarcinoma, investigators reported at the 2019 Gastrointestinal Cancers Symposium. In the NivoRam phase I/II stud...

see more →